Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998
In a recent article that appeared in the ARCHIVES, Frank and coworkers1 claimed that retinopathy and excessive retinal vascular endothelial growth factor production in galactosemic rats were inhibited by the administration of an aldose reductase inhibitor (ARI). These retinal abnormalities, being a result of the experimental galactosemia, should have been expected to be least severe in whichever animals happen to be least severely galactosemic, as judged, eg, from a comparison of their glycated hemoglobin levels. The mean glycated hemoglobin level in the 5 galactosemic rats given the ARI was found to be only about half the level found in the control galactosemic rats not given the drug; moreover, the level seems to be not statistically significantly greater than the level in normal (nongalactosemic) animals.
Engerman RL, Kern TS. Retinopathy and Tissue Hexose in Drug-Treated Animals. Arch Ophthalmol. 1998;116(4):543-544. doi: